These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 28987768)

  • 21. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
    J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
    Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
    Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
    Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
    Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
    Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
    Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.
    Mansoor W; Joo S; Norquist JM; Kato K; Sun JM; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Sunpaweravong P; Alsina M; Goekkurt E; Suryawanshi S; Shah S; Shen L
    Oncologist; 2024 Oct; 29(10):e1324-e1335. PubMed ID: 38815152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
    Schmid P; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Mejia JA; Zhou X; Haiderali A; Nguyen AM; Cortes J; Winer EP
    Eur J Cancer; 2023 Dec; 195():113393. PubMed ID: 37976633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Amonkar M; Yao L; Jin F; Norwood K; Maio M
    Gynecol Oncol; 2022 Aug; 166(2):245-253. PubMed ID: 35835611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
    Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A
    Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500
    [No Abstract]   [Full Text] [Related]  

  • 30. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
    Ryoo BY; Merle P; Kulkarni AS; Cheng AL; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Daniele B; Norquist JM; Chen E; Siegel AB; Zhu AX; Finn RS; Kudo M
    Cancer; 2021 Mar; 127(6):865-874. PubMed ID: 33231873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 32. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
    Vaughn DJ; Bellmunt J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Li H; Perini RF; Bajorin DF; de Wit R
    J Clin Oncol; 2018 Jun; 36(16):1579-1587. PubMed ID: 29590008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
    Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
    Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.
    von Tresckow B; Fanale M; Ardeshna KM; Chen R; Meissner J; Morschhauser F; Moskowitz C; Zinzani PL; Giezek H; Balakumaran A; Vo TT; Raut M; Brice P
    Leuk Lymphoma; 2019 Nov; 60(11):2705-2711. PubMed ID: 31012356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.
    Dent R; Cortés J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Haiderali A; Jia L; Nguyen AM; Pan W; O'Shaughnessy J; Schmid P
    J Natl Cancer Inst; 2024 Oct; 116(10):1654-1663. PubMed ID: 38913881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
    Robert C; Carlino MS; McNeil C; Ribas A; Grob JJ; Schachter J; Nyakas M; Kee D; Petrella TM; Blaustein A; Lotem M; Arance A; Daud AI; Hamid O; Larkin J; Anderson J; Krepler C; Grebennik D; Long GV
    J Clin Oncol; 2023 Aug; 41(24):3998-4003. PubMed ID: 37348035
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
    Adenis A; Kulkarni AS; Girotto GC; de la Fouchardiere C; Senellart H; van Laarhoven HWM; Mansoor W; Al-Rajabi R; Norquist J; Amonkar M; Suryawanshi S; Bhagia P; Metges JP
    J Clin Oncol; 2022 Feb; 40(4):382-391. PubMed ID: 34730989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.
    Maio M; Amonkar MM; Norquist JM; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Wang R; Norwood K; Marabelle A
    Eur J Cancer; 2022 Jul; 169():188-197. PubMed ID: 35588692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394.
    Qin S; Fang W; Ren Z; Ou S; Lim HY; Zhang F; Lee KC; Choi HJ; Tong J; Tao M; Xu A; Cheng A; Lu CH; Chiu CF; Abdul Wahid MI; Kamble S; Norquist JM; Zhong W; Li C; Chen Z
    Liver Cancer; 2024 Aug; 13(4):389-400. PubMed ID: 39114760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.